In 2021, the BPH treatment industry was worth around USD 11,892.8 million, and it is projected to advance at a 5.2% CAGR from 2021 to 2030, hitting USD 18,837.7 million by 2030, according to P&S Intelligence.
This growth can be credited to the growing favor for minimally invasive operations, the rising occurrence of BPH, and growing grants, investments, and funds for directing research on new treatments.
 |
| Get the sample pages of this report: https://bit.ly/3F8xBT1 |
Operation is an improved substitute to the management of BPH through medicine, but patients are leaning more towards the medicine because of the post-surgery harm to the body done by surgical burns and cuts. The growth of minimally invasive techniques has brought an alteration in patients’ perceptions and given medical device manufacturers a competitive advantage.
North America held the largest market share, of 41.0%, in 2021. The rising occurrence of the issue is boosting the acceptance of cutting-edge treatments, including prostatic stenting, laser therapy, and UroLift therapy, thus fuelling the market growth in the continent.
Additionally, the supportive reimbursement guidelines and an increasing number of skilled surgeons will aid the advance of the players in the continent in the coming few years.
The APAC region is projected to experience the fastest development in the coming few years, at a CAGR of 6.4%. The thriving disposable income and spending ability, rising living standards, growing urological illness burden, and increasing expenditure in the healthcare industry expand the progress.
Hence, growing favor for minimally invasive operations, rising occurrence of BPH, and growing grants, investments, and funds for directing research on new treatments are the major factors propelling the BPH treatment industry.
No comments:
Post a Comment